{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:34:47Z","timestamp":1756895687600,"version":"3.37.3"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1590,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Amgen, Pfizer, Inc."},{"DOI":"10.13039\/501100014841","name":"Medac GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1093\/annonc\/mdv205","type":"journal-article","created":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T02:21:15Z","timestamp":1430274075000},"page":"1434-1440","source":"Crossref","is-referenced-by-count":11,"title":["Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML\u2014long-term results of a prospective randomized intergroup study of the East German Study Group Hematology\/Oncology (OSHO) and the Study Alliance Leukemia (SAL)"],"prefix":"10.1016","volume":"26","author":[{"given":"A.","family":"Thiel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"P\u00f6nisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Aulitzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Maschmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Neugebauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Morgner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Kroschinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv205_bb0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/157488706776876445","article-title":"Treatment of relapsed acute myeloid leukaemia","volume":"1","author":"Kell","year":"2006","journal-title":"Rev Recent Clin Trials"},{"key":"10.1093\/annonc\/mdv205_bb0015","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2005-10-4202","article-title":"Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial","volume":"107","author":"Milligan","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv205_bb0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2141.2001.02785.x","article-title":"Comparison of \u2018sequential\u2019 versus \u2018standard\u2019 chemotherapy as re-induction treatment, with or without cyclosporine, in refractory\/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial","volume":"113","author":"Liu Yin","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdv205_bb0025","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","article-title":"The myth of the second remission of acute leukemia in the adult","volume":"121","author":"Forman","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv205_bb0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood.V64.1.54.54","article-title":"Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells","volume":"64","author":"Kufe","year":"1984","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv205_bb0035","first-page":"513","article-title":"High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia","volume":"81","author":"Clavio","year":"1996","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdv205_bb0040","first-page":"653","article-title":"Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule","volume":"2","author":"Seymour","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv205_bb0045","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2003-07-2195","article-title":"The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients","volume":"103","author":"Ossenkoppele","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv205_bb0050","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv205_bb0055","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/leu.2013.297","article-title":"Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG","volume":"28","author":"Fiegl","year":"2014","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdv205_bb0060","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1080\/1042819021000006529","article-title":"The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature","volume":"43","author":"Leopold","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdv205_bb0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2012-07-444851","article-title":"Sense and nonsense of high-dose cytarabine for acute myeloid leukemia","volume":"121","author":"L\u00f6wenberg","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv205_bb0070","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","article-title":"High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 Trial","volume":"32","author":"Willemze","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv205_bb0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.21351","article-title":"Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study","volume":"84","author":"Kim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdv205_bb0080","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1182\/blood-2012-10-464149","article-title":"Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients","volume":"121","author":"Gamazon","year":"2013","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/7\/1434\/16702925\/mdv205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:54:09Z","timestamp":1624521249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419345156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0923753419345156"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv205","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}